The rise of Sildenafil initially sparked a period of growth for major pharmaceutical companies, nevertheless recent shifts present a complicated scenario for investors. Lower-cost versions are reducing revenue, and https://joshascd402407.blogvivi.com/41776349/sildenafil-and-big-pharma-a-risky-investment